Suppr超能文献

基于BRCA突变谱的高危乳腺癌患者的临床和病理特征:一项回顾性研究

Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.

作者信息

Atcı Muhammed Mustafa, Geredeli Çağlayan, Ay Seval, Sakin Abdullah, Ertürk Biray, Seçmeler Şaban, Arıcı Serdar, Çekin Ruhper, Yaşar Nurgül, Can Orçun, Cihan Şener, Gümüş Mahmut

机构信息

Clinic of Medical Oncology, İstanbul Professor Doctor Cemil Tasçıoğlu City Hospital, İstanbul, Turkey.

Department of Medical Oncology, Medeniyet University, Göztepe Training and Research Hospital, İstanbul, Turkey.

出版信息

Eur J Breast Health. 2021 Mar 31;17(2):123-127. doi: 10.4274/ejbh.galenos.2020.6346. eCollection 2021 Apr.

Abstract

OBJECTIVE

This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2) .

MATERIALS AND METHODS

This study enrolled patients with invasive breast cancer who have been evaluated for BRCA1/2 mutations due to the presence of high-risk factors admitted to two tertiary referral centers in Turkey. Clinical and histopathological features were analyzed in BRCA1 mutation carriers, BRCA2 mutation carriers, and non-carriers.

RESULTS

A total of 302 patients with a mean age of 44.2±9.9 (22-82) years were included. BRCA1/2 mutation was found in 75 (24%) patients, of whom 41 (13.6%) were BRCA1 mutation carriers and 37 (12.3%) were BRCA2 mutation carriers. Moreover, 104 (34.4%) and 4 (1.3%) patients had family history of breast and ovarian carcinoma, respectively. The rates of triple negativity (56.1%), histologic grade 3 (65.9%), and lymphovascular invasion (78%) were significantly higher in BRCA1 mutation carriers than in non-carriers and BRCA2 mutation carriers. Furthermore, 87% of triple-negative BRCA1 mutation carriers had histologic grade 3 tumors compared with 38.9% in non-triple-negative BRCA1 mutation carriers, and the difference was significant.

CONCLUSION

Findings of this study showed that BRCA1-related breast cancers represent a distinct group with unique pathological features, which are usually associated with a poor prognosis.

摘要

目的

本研究旨在根据两个乳腺癌易感基因(BRCA1/2)的突变状态,确定土耳其高危乳腺癌患者的临床病理特征差异。

材料与方法

本研究纳入了因存在高危因素而在土耳其两家三级转诊中心接受BRCA1/2突变评估的浸润性乳腺癌患者。对BRCA1突变携带者、BRCA2突变携带者和非携带者的临床和组织病理学特征进行了分析。

结果

共纳入302例患者,平均年龄44.2±9.9(22 - 82)岁。75例(24%)患者检测到BRCA1/2突变,其中41例(13.6%)为BRCA1突变携带者,37例(12.3%)为BRCA2突变携带者。此外,分别有104例(34.4%)和4例(1.3%)患者有乳腺癌和卵巢癌家族史。BRCA1突变携带者的三阴性率(56.1%)、组织学3级率(65.9%)和淋巴管浸润率(78%)显著高于非携带者和BRCA2突变携带者。此外,87%的三阴性BRCA1突变携带者有组织学3级肿瘤,而非三阴性BRCA1突变携带者的这一比例为38.9%,差异有统计学意义。

结论

本研究结果表明,BRCA1相关乳腺癌代表了一个具有独特病理特征的不同群体,通常预后较差。

相似文献

1
Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.
Eur J Breast Health. 2021 Mar 31;17(2):123-127. doi: 10.4274/ejbh.galenos.2020.6346. eCollection 2021 Apr.
2
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16.
3
Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.
Hugo J. 2009 Dec;3(1-4):63-76. doi: 10.1007/s11568-010-9136-z. Epub 2010 Apr 10.
4
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
J Clin Oncol. 2008 Sep 10;26(26):4282-8. doi: 10.1200/JCO.2008.16.6231.
7
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat. 2017 Jun;163(3):565-571. doi: 10.1007/s10549-017-4198-4. Epub 2017 Mar 25.

引用本文的文献

1
Updates on Lymphovascular Invasion in Breast Cancer.
Biomedicines. 2023 Mar 21;11(3):968. doi: 10.3390/biomedicines11030968.
2
Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.
Front Oncol. 2022 May 26;12:907684. doi: 10.3389/fonc.2022.907684. eCollection 2022.
3
Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients.
Cancer Res Treat. 2022 Jul;54(3):827-833. doi: 10.4143/crt.2021.791. Epub 2021 Oct 13.
4
Identification of Eleven Novel Mutations in Tunisia: Impact on the Clinical Management of Related Cancers.
Front Oncol. 2021 Aug 20;11:674965. doi: 10.3389/fonc.2021.674965. eCollection 2021.

本文引用的文献

1
Lymph Node Ratio Predicts Long-Term Survival in Lymph Node-Positive Breast Cancer.
Eur J Breast Health. 2020 Jul 29;16(4):270-275. doi: 10.5152/ejbh.2020.5809. eCollection 2020 Oct.
3
Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population.
Int J Breast Cancer. 2019 Jan 1;2019:9645147. doi: 10.1155/2019/9645147. eCollection 2019.
4
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.
5
BRCA mutation genetic testing implications in the United States.
Breast. 2017 Feb;31:224-232. doi: 10.1016/j.breast.2016.11.021. Epub 2016 Dec 6.
6
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
Breast J. 2015 May-Jun;21(3):260-7. doi: 10.1111/tbj.12392. Epub 2015 Mar 19.
7
Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
Ann Surg Oncol. 2014 Oct;21(10):3324-9. doi: 10.1245/s10434-014-3904-2. Epub 2014 Jul 22.
8
BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.
Cancer Invest. 2014 Oct;32(8):375-87. doi: 10.3109/07357907.2014.919302. Epub 2014 Jun 2.
10
Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.
BMC Cancer. 2010 Apr 16;10:145. doi: 10.1186/1471-2407-10-145.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验